PD-L1抑制剂——Atezolizumab的药理作用和临床评价

Pharmacological and clinical evaluation of PD-L1 inhibitor:Atezolizumab

Atezolizumab(商品名:Tecentriq^(TM))是由基因泰克公司开发的一种针对程序性死亡配体1(PD-L1或CD274抗原)的单克隆抗体,用于治疗各种血液恶性肿瘤和实体瘤。该药物已被FDA批准为治疗尿路上皮癌的二线药物,并有望成为非小细胞肺癌的二线治疗药物。本文对其作用机制、药动学、临床研究和不良反应等进行综述。

Atezolizumab(TecentriqTM),a monoclonal antibody targeting programmed death ligand 1(PD-L1 or CD274 antigen),is developed by Genentech as treatment for a variety of hematological malignancies and solid tumors.It has been approved by FDA as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer.This article summarizes the mechanism,pharmacokinetics,clinical studies and adverse events of Atezolizumab.